FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009772297> ?p ?o ?g. }

• W2009772297 abstract "Ribonucleotide reductase is a key enzyme in DNA replication and, as such, has been a target for antitumor agents. This enzyme is composed of two nonidentical protein subunits which can be specifically and independently inhibited. Combinations of drugs directed at the effector-binding and non-heme iron subunits of ribonucleotide reductase resulted in the synergistic inhibition of L1210 cell growth and synergistic L1210 cell kill. These combinations included dAdo/EHNA/IMPY/Desferal; dAdo/EHNA/hydroxyurea/Desferal (the EHNA was required to protect dAdo from deamination while Desferal modulated the effects of IMPY or hydroxyurea); 2-F-araA/IMPY/Desferal and 2-F-2'-dAdo/IMPY/Desferal (EHNA was not required to protect 2-F-araA or 2-F-2'-dAdo from deamination); and dGuo/8-AGuo/IMPY/Desferal (8-AGuo was required to protect dGuo from phosphorolysis). Although thymidine alone inhibited L1210 cell growth, it was not possible to potentiate the effects of thymidine with the pyrimidine nucleoside phosphorylase inhibitors, acyclothymidine, 5-chlorouracil and 2,6-dihydroxypyridine. Combinations of drugs directed at the ribonucleotide reductase and DNA polymerase sites were studied for their effects on L1210 cell growth. With these combinations, no synergistic inhibition of L1210 cell growth was observed. The combinations of aphidicolin and IMPY/Desferal and aphidicolin and dAdo/EHNA inhibited L1210 cell growth in an additive manner; the combinations of IMPY/Desferal and BuAU or IMPY/Desferal and BuPdG resulted in antagonistic inhibition of L1210 cell growth. From these results it is clear that combination chemotherapy directed at independent sites of the same key target enzyme can result in strong synergistic inhibition of cell growth and cytotoxicity offering a clear therapeutic advantage. In contrast, the combinations directed at sequential key enzymes (e.g. ribonucleotide reductase and DNA polymerase) did not result in synergistic inhibition of cell growth. The utility of combinations of drugs directed at specific but independent sites of the target enzyme (e.g. ribonucleotide reductase) has been demonstrated in tumor cell systems in culture and now must be demonstrated in vivo." @default.
• W2009772297 created "2016-06-24" @default.
• W2009772297 creator A5004736150 @default.
• W2009772297 creator A5011154182 @default.
• W2009772297 creator A5082444475 @default.
• W2009772297 creator A5082651430 @default.
• W2009772297 creator A5091322129 @default.
• W2009772297 date "1985-01-01" @default.
• W2009772297 modified "2023-10-02" @default.
• W2009772297 title "The utility of combinations of drugs directed at specific sites of the same target enzyme — ribonucleotide reductase as the model" @default.
• W2009772297 cites W1485608018 @default.
• W2009772297 cites W1535441861 @default.
• W2009772297 cites W1602075271 @default.
• W2009772297 cites W1979767153 @default.
• W2009772297 cites W1982099465 @default.
• W2009772297 cites W1990699846 @default.
• W2009772297 cites W1992890999 @default.
• W2009772297 cites W2014029449 @default.
• W2009772297 cites W2018325422 @default.
• W2009772297 cites W2032903115 @default.
• W2009772297 cites W2049900538 @default.
• W2009772297 cites W2054137828 @default.
• W2009772297 cites W2058704920 @default.
• W2009772297 cites W2081059256 @default.
• W2009772297 cites W2083399404 @default.
• W2009772297 cites W2089541054 @default.
• W2009772297 cites W2089709035 @default.
• W2009772297 cites W2167789540 @default.
• W2009772297 doi "https://doi.org/10.1016/0065-2571(85)90047-0" @default.
• W2009772297 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3907303" @default.
• W2009772297 hasPublicationYear "1985" @default.
• W2009772297 type Work @default.
• W2009772297 sameAs 2009772297 @default.
• W2009772297 citedByCount "7" @default.
• W2009772297 crossrefType "journal-article" @default.
• W2009772297 hasAuthorship W2009772297A5004736150 @default.
• W2009772297 hasAuthorship W2009772297A5011154182 @default.
• W2009772297 hasAuthorship W2009772297A5082444475 @default.
• W2009772297 hasAuthorship W2009772297A5082651430 @default.
• W2009772297 hasAuthorship W2009772297A5091322129 @default.
• W2009772297 hasConcept C104292427 @default.
• W2009772297 hasConcept C104317684 @default.
• W2009772297 hasConcept C185592680 @default.
• W2009772297 hasConcept C4710235 @default.
• W2009772297 hasConcept C55493867 @default.
• W2009772297 hasConcept C86803240 @default.
• W2009772297 hasConcept C98274493 @default.
• W2009772297 hasConceptScore W2009772297C104292427 @default.
• W2009772297 hasConceptScore W2009772297C104317684 @default.
• W2009772297 hasConceptScore W2009772297C185592680 @default.
• W2009772297 hasConceptScore W2009772297C4710235 @default.
• W2009772297 hasConceptScore W2009772297C55493867 @default.
• W2009772297 hasConceptScore W2009772297C86803240 @default.
• W2009772297 hasConceptScore W2009772297C98274493 @default.
• W2009772297 hasLocation W20097722971 @default.
• W2009772297 hasLocation W20097722972 @default.
• W2009772297 hasOpenAccess W2009772297 @default.
• W2009772297 hasPrimaryLocation W20097722971 @default.
• W2009772297 hasRelatedWork W1596026758 @default.
• W2009772297 hasRelatedWork W2013557655 @default.
• W2009772297 hasRelatedWork W2015837247 @default.
• W2009772297 hasRelatedWork W2051637434 @default.
• W2009772297 hasRelatedWork W2064720997 @default.
• W2009772297 hasRelatedWork W2067430655 @default.
• W2009772297 hasRelatedWork W2092819453 @default.
• W2009772297 hasRelatedWork W2165668252 @default.
• W2009772297 hasRelatedWork W2466670781 @default.
• W2009772297 hasRelatedWork W2899084033 @default.
• W2009772297 isParatext "false" @default.
• W2009772297 isRetracted "false" @default.
• W2009772297 magId "2009772297" @default.
• W2009772297 workType "article" @default.